Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 123 posts  |  Last Activity: 7 hours ago Member since: Mar 5, 1998
  • Reply to

    Parkinson's clinical trials in U.S.?

    by hammer61 Nov 25, 2015 9:24 AM
    biotech_invest biotech_invest Nov 25, 2015 10:58 AM Flag

    well, I see that PRAN pumpers started to play Parkinson's Disease card :-) May be it's too early? PBT434 is one of many Prana fake drugs and pumping PRAN stock with one more fake drug is useless :-)
    Pumper's moderator, please switch these "dumb and dumber" couple to HD direction :-) Even if Ph1 PD started in 2016 it will not add even 5 cents to PRAN pps :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 24, 2015 6:35 PM Flag

    come on, each your comment only prove that you are an idiot :-)
    You are in a hole of stupidity :-) If you don't understand what is allegory you brain is absolutely senile.
    There is no any racism in the joke "this study is for Chinese post-docs" and even Chinese scientists never complain about this term.
    Continue the as..kissing process for Tanzi and his collaborators :-)

  • biotech_invest biotech_invest Nov 24, 2015 12:47 PM Flag

    Enig, are you really so stupid? "This study is for Chinese post-docs" is just an allegory, it's not about any nationality :-) Who care what is origination of these Choi or Kim? If Tanzi collaborates with these two guys he definitely likes the results they produce i.e. PBT2 is very strong AD/HD drug that showed very promising results in their Petri models.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 23, 2015 5:44 PM Flag

    So you bet on Europe? :-) And think that Europe will approve PBT2 for HD because of the results of Ph2 trial? Are you sure that your brain is OK? You should test your brain immediately i.e. for example solve some simple challenge at InnoCentive. I'll recommend you "Localized Skin Cooling": not complicate and the award $15,000 USD is not so bad. When you solve it and got an award just put your YMB ID inside of your avatar picture (like I_T) and we will never worry about your brain :-)
    But now when you wrote "accererated approval" we are worry. May be it's AD? Even excellent speller starts misspelling words at early stage of AD.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 23, 2015 4:59 PM Flag

    no seeing the pattern is a biggest mistake in investment :-)
    For MNKD pattern was simple: Mann step down and allow MNKD pps decline from average $10 to current $2 during last 1.5 year. Funds/institutions increase their stakes 30% from 76M to current 111M. MNKD SI increased to record 131M in 5/29/2015 and now it declining during last 3 reports from 127M to 120M.
    Everything was done to sell MNKD for modest pps like $10-12 to avoid any lawsuits and scandals. Mann will leave as a winner, funds/institutions will have very good gain but shorts that didn't covered will have enough big losses. Happy end for everybody, besides some stupid stubborn shorts.
    see the pattern and you will never lose money in investment :-) especially in investment in biotech area.
    Pattern for PRAN is simple: 1) this scam will survive this time and PCH will be lifted; 2) pps will spike to $2-3 range on news and then decline to $1.50 and lower for many years; 3) after 3-4 years pps will grow again to $4-5 range and spike to $10-12 before Ph3 HD trial results release; 4) after Ph3 HD trial fail Prana will switch to PD program to survive... So, it will be very long story, guys and I'm will be here with you, my pumpers friends itm, kad, piv, enig... And of course Rouge Kansas Farter with variable number after rkf :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 23, 2015 4:07 PM Flag

    The opportunity to be post-doc at Tanzi made me LOL! You know what mean such term as "this study is for Chinese post-docs"? Will explain: if you want always have very good results in your lab just hire Chinese postdocs (or collaborate with them). The results that they will produce will always satisfy you but these results will never be reproducible :-)
    So, when I see names of Tanzi collaborators i.e. Se Hoon Choi and Dr. Doo-Yeon Kim I know just one thing: PBT2 will always show perfect results for AD, HD, PD and any other diseases :-) But only in labs of Tanzi and these two guys (Chinese and Korean) :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 23, 2015 3:47 PM Flag

    it's good, never ever listen to bio :-) never buy MNKD especially now when big holders increased holding during Q3 when pps was declined very sharp. Funds/institutions are too stupid: they are buying "falling knife" MNKD but never PRAN :-) PRAN Institutional Ownership 00.75% but MNKD Institutional Ownership 27.21% and Mann friends 4 biggest holders have added between 0.5% to 28%:

    Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
    VANGUARD GROUP INC 09/30/2015 18,183,510 480,725 2.72 44,913
    BLACKROCK FUND ADVISORS 09/30/2015 11,968,435 561,297 4.92 29,562
    STATE STREET CORP 09/30/2015 10,472,519 2,343,056 28.82 25,867
    FMR LLC 09/30/2015 9,264,968 50,000 .54 22,884

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 23, 2015 3:40 PM Flag

    so you bough my shares at $1.05? LOL! You have giant gain now. The truth is that only recent new buyers around $0.80 have some gain now. No one old holder has the gain, only losses (sometimes giant ones).
    BTW, I don't care about Tanzi and never was "involved" with him. He is just stubborn and dishonest scientist that can't admit that all money that he got on AD research and test of his stupid "metal theory" were spend on nothing. PBT2 and other metal chelators will never cure AD, HD, PD or other diseases. Hope he will do it at some point of his life.

    Sentiment: Strong Sell

  • story about genius Tanzi that put his life to discover the cure for AD, HD, PD etc but Big Pharma and funds didn't wanted Prana to be successful and paid money to doctors that gave Aricept to placebo group instead of sugar pills :-) And now these predators are waiting for right moment to swallow PRAN. PBT2 dosed at 500 mg will for sure reverse AD, HD and cure patients but FDA officers are also corrupted, they put PCH on Ph3 HD and want PRAN to dose useless 100 mg. LOL! It can be tremendous story that will induce huge pps spike to $1.10 :-)

    Sentiment: Strong Sell

  • Several traders continuously increasing bid and other buying at any prices. Then buyers put higher bid and sellers are buying back at higher. With 1M float they can easy reach $100. It's 100% manipulation but SEC is not interfere with this obvious Ponzi pattern. Question is why?
    This biotech has nothing valuable and will never have. Lenzilumab already failed a Phase II trial for severe asthma by missing its primary clinical endpoint of improvement in forced expiratory volume in 1 second (FEV1) compared to placebo. It's a fake drug that will cure nothing.
    Any way, KBIO is a good example that even scam fraud biotech companies can be pumped 4000% and then dumped without any punishment from SEC.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 23, 2015 2:18 PM Flag

    looks like this "joke" continues and will end at pps $1. Same about DARA transaction.

    Sentiment: Strong Buy

  • Reply to

    Nice comments about Rudy Tanzi

    by interestingtome Nov 21, 2015 10:01 PM
    biotech_invest biotech_invest Nov 23, 2015 12:50 PM Flag

    LOL! PRAN pps is 1 cent higher than I sold it with -9% losses. You Tanzi's as..kissers were working very hard to pump this scam from $0.7 to $1.05. But don't be so glad - it's not your achievement. The combination of possible lift of PCH for Ph3 HD and historically lowest pps pushed some naive investors to buy. But I bet on two other scams in AD area: AVXL and AXON. Both are green and will make more money than PRAN. With PRAN recent investors will have very soon an effect of some simple rule: buy the rumor sell news. Now rumor is that PRAN will lift Ph3 HD in early 2016. When they lift it (better say if...) everybody will sell news. Because Ph3 HD will take at least 3-4 years and 15-20 millions. Who will keep PRAN 3-4 years at pps $2? Then in 2018-2019 we will see again a spike in PRAN pps because soon results release of Ph3 HD. Too long story.
    Both AVXL and AXON AD results will be released in 2017. Not too long story. TauRx Ph3 AD results release in May-June 2016 will add intrigue in AD area.

    Sentiment: Strong Sell

  • Reply to

    Nice comments about Rudy Tanzi

    by interestingtome Nov 21, 2015 10:01 PM
    biotech_invest biotech_invest Nov 23, 2015 10:40 AM Flag

    oh come on, your Tanzi as..kissing panegyrics already become annoying :-)There is a line of PRAN pumpers that are ready to add one more kiss to Tanzi's as...
    Just one question: if he is so brilliant where are the AD patients that were cured by AD drug that he is invented (doesn't matter PBT2 or gamma secretase modulators)? His fake drug cure no one AD patient and never will. Because so-called "Metal hypothesis of Alzheimer’s disease” (this time you have use correct term HYPOTHESIS but not theory) is a complete BS. When real AD drug will be discovered everybody will know that Tanzi stupid hypothesis only mislead AD research and postpone the discovering of real drug.
    It will fatal mistake for PRAN to continue talk about AD direction. Ph3 HD will give them 3-4 years of happy life before trial results release :-) And investors will also have a good opportunity to make money on this scam.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 20, 2015 3:54 PM Flag

    So, you are still not learning one very important thing in this life: Never say never :-)
    Everybody knows that Mann group together with other holders own around 60% of outstanding shares now and 4 big holders increase their stakes for Q3, 2015. SI is 120M or almost 45% of float. Bid for 30M shares at Market will seed huge panic and shorts will cover at any price. KBIO has 4M out and Shkrelli bought 70% of float without significant increasing of pps. Now they control price because current shorts are completely burned. But other shorts are coming and will short at $20. Shkrelli and his cronies will burn tons on money to fight with shorts but since KBIO is scam it's very unlikely that they will win this risky game.
    MNKD is not a scam biotech and Technosphere technology cost at least several billion. Mann is old but he can't leave the arena as looser. Selling MNKD at $10-12 range will make him a winner.

    Sentiment: Strong Buy

  • KBIO shorts were burned alive and their pain is unbelievable and still grow. KBIO pps behavior is 100% obvious manipulation but looks like SEC doesn't care.
    Any way it's a very good lesson for all shorts: don't play with fire. Mann is old but he is not senile. And he has many friends that are very rich.
    Looks like that next drug for lung delivery via Technosphere technology will be a pain-killer (general or migraine). And next partner can also pay very significant milestones to MNKD. Also Mann personally promised Europe approval for Afrezza right after FDA approval.
    Mann come to win here, not to loose.

    Sentiment: Strong Buy

  • Sure it was some mutual agreement between Mann and Sanofi: firstly to induce the "artificial" decline of pps, blame "new" CEO and then sell company for pps that was at time of FDA approval of Afrezza. Good design!
    Who will sue Mann for low buyout price now? Only idiots...
    BTW, 4 biggest MNKD holders still adding positions even after 1 year pps decline. Are they complete idiots to buy "falling knife" stock?

    Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
    VANGUARD GROUP INC 09/30/2015 18,183,510 480,725 2.72 43,822
    BLACKROCK FUND ADVISORS 09/30/2015 11,968,435 561,297 4.92 28,844
    STATE STREET CORP 09/30/2015 10,472,519 2,343,056 28.82 25,239
    FMR LLC 09/30/2015 9,264,968 50,000 .54 22,329

    Sentiment: Strong Buy

  • In my Biotech scams list ORMP is "scammiest" biotech company (sure some idiot PRAN pumpers will immediately attack this neologism, but if they know another word please notify me). But look where ORMP pumpers publish their panegyric papers: Bloomberg, Barrons, TheStreet etc. One papers written by author Sharon has title "The Importance Of Being Oral" :-) Prana should hire to write something like "The Importance Of Being Zinc chelator and ionophore PBT2"
    PCH for Ph3 HD is still in action. It will be sad if Prana can't lift it with treatment dose 250 mg PBT2 daily - in this case PRAN pps will drop to $0.5 and below and only reverse split will save it from delisting. But reverse split is not positive event for scam biotechs. Look at AEZS: today reverse split 1/100 not saved pps besides the company said that First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen™ for the evaluation of AGHD. BTW pps before split was $0.04 and current Market Cap: 2.43B at Yahoo is just a mistake. Real one is around $19M.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Nov 19, 2015 3:41 PM Flag

    sure, they have studying this drug during several years already
    Last news about J147 were it also seems to slow ageing. "A drug tested on mice as a potential preventative against Alzheimer's disease had a range of unexpected anti-ageing effects."
    J147 is just an example of AD drugs that not directly target tau or amyloid plaques. So, the increasing of endogenous production of BDNF/NGF can be very promising approach in AD curing.

  • disease mice
    "When administered in food at a stage when pathology is advanced in 20-month-old transgenic AD mice, J147 rescued the severe loss of cognitive function, reduced soluble levels of Ab and increased neurotrophic factors essential for memory. When compared to donepezil in memory assays, J147 performed equally well or superior, and even showed synergistic effects in the fear conditioning assay. In addition, J147 has good medicinal chemical and pharmacological properties for a CNS drug, has few off-target effects and is orally active. Thus, J147 is an exciting, new compound with strong potential to be an AD therapeutic by slowing disease progression through neuroprotection as well as providing rapid cognition benefits by reversing cognition deficits following short-term treatment. These dual attributes improve the chances for success in clinical trials as a disease-modifying drug, and seems ideally suited for rapid progress through the new FDA guidelines for AD trials. We hypothesize that the mechanism of action of J147 is related to its ability to increase the levels of BDNF and NGF, and studies are being conducted to identify its molecular target."
    So, J147 is not a metal chelator and ionophore. I'm 100% agreed that BDNF and NGF are very important player in AD etiology. Just surprised that Big Pharma is still not license J147 from Salk - it might be a huge breakthrough in AD area.

  • It's good to have such model in that your compound is so effective :-) Especially if nobody has this model in lab and can't reproduce the results :-) If they got nothing or negative results in other models you can always say they other labs have bad AD models.
    PRAN pumpers are very excited today by this unexpected +17% pps jump. May be they will have some bonus today for such big success :-) Good job!

    Sentiment: Strong Sell

SNY
38.87-0.34(-0.87%)Feb 9 4:02 PMEST